SG11202009371WA - Methods for treating atopic dermatitis by administering an il-4r inhibitor - Google Patents
Methods for treating atopic dermatitis by administering an il-4r inhibitorInfo
- Publication number
- SG11202009371WA SG11202009371WA SG11202009371WA SG11202009371WA SG11202009371WA SG 11202009371W A SG11202009371W A SG 11202009371WA SG 11202009371W A SG11202009371W A SG 11202009371WA SG 11202009371W A SG11202009371W A SG 11202009371WA SG 11202009371W A SG11202009371W A SG 11202009371WA
- Authority
- SG
- Singapore
- Prior art keywords
- administering
- inhibitor
- methods
- atopic dermatitis
- treating atopic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862670824P | 2018-05-13 | 2018-05-13 | |
US201962840493P | 2019-04-30 | 2019-04-30 | |
PCT/US2019/031801 WO2019222055A1 (fr) | 2018-05-13 | 2019-05-10 | Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202009371WA true SG11202009371WA (en) | 2020-10-29 |
Family
ID=66641513
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202009371WA SG11202009371WA (en) | 2018-05-13 | 2019-05-10 | Methods for treating atopic dermatitis by administering an il-4r inhibitor |
Country Status (12)
Country | Link |
---|---|
US (2) | US11292847B2 (fr) |
EP (1) | EP3793597A1 (fr) |
JP (2) | JP2021523188A (fr) |
KR (1) | KR20210010518A (fr) |
CN (1) | CN112153982A (fr) |
AU (1) | AU2019270940A1 (fr) |
BR (1) | BR112020020387A2 (fr) |
CA (1) | CA3099066A1 (fr) |
MA (1) | MA52624A (fr) |
MX (1) | MX2020012064A (fr) |
SG (1) | SG11202009371WA (fr) |
WO (1) | WO2019222055A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI697334B (zh) | 2013-06-04 | 2020-07-01 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
AU2015222951B2 (en) | 2014-02-28 | 2020-06-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating skin infection by administering an IL-4R antagonist |
CN107474134B (zh) | 2016-06-08 | 2021-07-27 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
JP2019531273A (ja) | 2016-09-01 | 2019-10-31 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Il−4rアンタゴニストを投与することによりアレルギーを予防又は処置するための方法 |
US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
PT3515465T (pt) | 2017-08-18 | 2024-03-04 | Regeneron Pharma | Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r |
EP3941589A1 (fr) | 2019-03-21 | 2022-01-26 | Regeneron Pharmaceuticals, Inc. | Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie |
CN114173816A (zh) * | 2019-08-05 | 2022-03-11 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗特应性皮炎的方法 |
US11504426B2 (en) | 2019-08-05 | 2022-11-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8808015D0 (en) | 1988-04-06 | 1988-05-05 | Ritter M A | Chemical compounds |
WO1990005183A1 (fr) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Recepteurs d'interleukine-4 |
EP0668774A1 (fr) | 1991-05-03 | 1995-08-30 | Seragen, Inc. | Molecules ciblees sur un recepteur de l'interleukine destinees a traiter l'arthrite inflammatoire |
JP3315427B2 (ja) | 1992-03-05 | 2002-08-19 | 大日本除蟲菊株式会社 | 皮膚炎治療剤 |
US5714146A (en) | 1992-08-26 | 1998-02-03 | Board Of Regents Of The University Of Washington | IL-4 bone therapy |
EP0604693A1 (fr) | 1992-12-29 | 1994-07-06 | Schering-Plough | Anticorps monoclonaux contre le récepteur de l'interleukine-4 humain et hydridomes les produisant |
ZA946875B (en) | 1993-09-07 | 1995-07-06 | Smithkline Beecham Corp | Recombinant il4 antibodies useful in treatment of il4 mediated disorders |
ES2259478T3 (es) | 1998-09-18 | 2006-10-01 | Dynavax Technologies Corporation | Metodos para tratar trastornos asociados con la ige y composiciones para este uso. |
ES2382891T3 (es) | 2000-05-26 | 2012-06-14 | Immunex Corporation | Uso de anticuerpos IL-4R y sus composiciones |
US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
KR100572408B1 (ko) | 2000-07-26 | 2006-04-19 | 가부시키가이샤 호오도 | 진양성 조성물 및 창상치유촉진 조성물 |
US20030103938A1 (en) | 2001-05-09 | 2003-06-05 | Alk-Abello A/S | Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio |
JP2004529180A (ja) | 2001-05-11 | 2004-09-24 | ノバルティス アクチエンゲゼルシャフト | IgE関連障害を処置するのに使用するための組成物 |
AU2002339121B2 (en) | 2001-05-23 | 2007-03-22 | Duotol Ab | Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof |
EP2298717B1 (fr) | 2001-11-30 | 2015-10-28 | Biogen MA Inc. | Anticorps dirigés contre des protéines chimiotactiques |
DK1527100T3 (da) | 2002-03-29 | 2009-09-07 | Schering Corp | Humane monoklonale antistoffer mod interleukin-5 og fremgangsm der og sammens tninger omfattende samme |
WO2004070011A2 (fr) | 2003-02-01 | 2004-08-19 | Tanox, Inc. | Anticorps ige anti-humains a affinite elevee |
US7923209B2 (en) | 2003-03-14 | 2011-04-12 | Anergis, S.A. | Allergen peptide fragments and use thereof |
ES2383809T3 (es) | 2003-11-07 | 2012-06-26 | Immunex Corporation | Anticuerpos que se unen al receptor de interleucina 4 |
US7884054B2 (en) | 2003-12-22 | 2011-02-08 | Amgen Inc. | Methods for identifying functional antibodies |
JP2008504806A (ja) | 2004-02-27 | 2008-02-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Il−4/il−13特異的ポリペプチドおよびその治療上の使用 |
US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
JP5234445B2 (ja) | 2004-10-05 | 2013-07-10 | 源一郎 杣 | 薬剤 |
WO2006083390A2 (fr) | 2004-12-07 | 2006-08-10 | Children's Hospital Medical Center | Eotaxine-3 dans l'oesophagite eosinophile |
TW200902555A (en) | 2005-01-03 | 2009-01-16 | Hoffmann La Roche | Antibodies against IL-13 receptor alpha 1 and uses thereof |
US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
JP4221018B2 (ja) | 2006-08-31 | 2009-02-12 | トヨタ自動車株式会社 | 頭部保護エアバッグ装置 |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
EP2069403B1 (fr) | 2006-10-02 | 2014-05-07 | Regeneron Pharmaceuticals, Inc. | Anticorps humains à haute affinité vis-à-vis du récepteur il-4 humain |
ES2478242T3 (es) | 2007-03-22 | 2014-07-21 | Genentech, Inc. | Anticuerpos anti IgE apoptóticos que se unen con el IgE unido a membrana |
EP2022507A1 (fr) | 2007-08-07 | 2009-02-11 | Universität Hamburg | Compositions d'anticorps spécifiques pour les épitopes des lgE, lgG4 et lgA en tant qu'outils pour la création de molécules hypoallergéniques pour l'immunothérapie spécifique |
US8637239B2 (en) | 2007-11-05 | 2014-01-28 | The Board Of Trustees Of The University Of Illinois | Minimally-invasive measurement of esophageal inflammation |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
DE202008006598U1 (de) | 2008-04-11 | 2008-10-02 | Alk-Abelló A/S | Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung |
US20090264392A1 (en) | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
US20120004205A1 (en) | 2008-12-01 | 2012-01-05 | Cincinnati Children's Hospital Medical Center | Il-13 induced gene signature for eosinophilic esophagitis |
WO2010120524A2 (fr) | 2009-03-31 | 2010-10-21 | Altair Therapeutics, Inc. | Procédés de modulation d'une réponse immunitaire à une infection virale |
US8497528B2 (en) | 2010-05-06 | 2013-07-30 | Taiwan Semiconductor Manufacturing Company, Ltd. | Method for fabricating a strained structure |
WO2011026966A2 (fr) | 2009-09-07 | 2011-03-10 | Dbv Technologies | Méthode de traitement d'oesophagite éosinophile |
US8993347B2 (en) | 2009-12-17 | 2015-03-31 | Cornell University | Methods for detecting antibodies in mucosal samples and device for sampling mucosal material |
EP2585075B8 (fr) | 2010-06-24 | 2021-09-22 | ViroPharma Biologics LLC | Méthodes de traitement de l'inflammation oesophagienne |
CA2813587C (fr) | 2010-10-06 | 2019-01-15 | Regeneron Pharmaceuticals, Inc. | Formulations stabilisees contenant des anticorps anti-recepteur de l'interleukine-4 (il-4r) |
RU2453303C1 (ru) | 2010-12-23 | 2012-06-20 | Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") | Фармацевтическая композиция для лечения атопического дерматита |
EP2661631A4 (fr) | 2011-01-06 | 2014-05-21 | Childrens Hosp Medical Center | Profils d'expression de cytokine sophagienne dans l' sophagite à éosinophiles |
US20130052190A1 (en) | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
US9928344B2 (en) | 2011-06-21 | 2018-03-27 | Children's Hospital Medical Center | Diagnostic methods of eosinophilic esophagitis |
WO2013051928A1 (fr) | 2011-10-06 | 2013-04-11 | N.V. Nutricia | Traitement de l'œsophagite à éosinophiles |
EP2790696A1 (fr) | 2011-12-16 | 2014-10-22 | Atopix Therapeutics Limited | Combinaison d'un antagoniste de crth2 et d'un inhibiteur de pompe à protons pour le traitement de l' sophagite à éosinophiles |
KR20140119777A (ko) | 2012-01-31 | 2014-10-10 | 제넨테크, 인크. | 항-ig-e m1'' 항체 및 그의 사용 방법 |
WO2013155010A1 (fr) | 2012-04-09 | 2013-10-17 | Children's Hospital Medical Center | Biomarqueurs non invasifs pour l'œsophagite éosinophile |
WO2014031610A1 (fr) | 2012-08-21 | 2014-02-27 | Sanofi | Procédés permettant de traiter ou d'empêcher l'asthme par administration d'un antagoniste du récepteur à l'interleukine 4 (il-4r) |
EP4374919A2 (fr) | 2012-09-07 | 2024-05-29 | Regeneron Pharmaceuticals, Inc. | Méthodes de traitement de la dermatite atopique par administration d'un antagoniste de l'il-4r |
US10132809B2 (en) | 2012-10-10 | 2018-11-20 | Rhote Island Hospital | Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis |
US10077315B2 (en) | 2013-02-05 | 2018-09-18 | Engmab Sàrl | Bispecific antibodies against CD3 and BCMA |
TWI697334B (zh) | 2013-06-04 | 2020-07-01 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
US10059771B2 (en) | 2013-06-21 | 2018-08-28 | Sanofi Biotechnology | Methods for treating nasal polyposis by administering an IL-4R antagonist |
TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
CA2940295A1 (fr) | 2014-02-21 | 2015-08-27 | Sanofi Biotechnology | Methodes de traitement ou de prevention de l'asthme par administration d'un antagoniste d'il-4 r |
AU2015222951B2 (en) | 2014-02-28 | 2020-06-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating skin infection by administering an IL-4R antagonist |
CA2967602A1 (fr) | 2014-11-14 | 2016-05-19 | Sanofi Biotechnology | Methodes de traitement de la sinusite chronique avec polypose nasale par administration d'un antagoniste d'il-4r |
KR20180110089A (ko) | 2016-02-19 | 2018-10-08 | 리제너론 파아마슈티컬스, 인크. | Il-4r 길항제를 투여함으로써 백신의 효능을 향상시키는 방법 |
CN107474134B (zh) | 2016-06-08 | 2021-07-27 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
TWI728172B (zh) | 2016-08-18 | 2021-05-21 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
JP2019531273A (ja) | 2016-09-01 | 2019-10-31 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Il−4rアンタゴニストを投与することによりアレルギーを予防又は処置するための方法 |
US11845803B2 (en) | 2017-02-17 | 2023-12-19 | Fred Hutchinson Cancer Center | Combination therapies for treatment of BCMA-related cancers and autoimmune disorders |
WO2018201051A1 (fr) | 2017-04-28 | 2018-11-01 | Novartis Ag | Agent ciblant le bcma et polythérapie incluant un inhibiteur de gamma-sécrétase |
US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
PT3515465T (pt) | 2017-08-18 | 2024-03-04 | Regeneron Pharma | Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r |
ES2969049T3 (es) | 2017-10-30 | 2024-05-16 | Sanofi Biotechnology | Antagonista de IL-4R para uso en un método para tratar o prevenir el asma |
EP3941589A1 (fr) | 2019-03-21 | 2022-01-26 | Regeneron Pharmaceuticals, Inc. | Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie |
US11504426B2 (en) | 2019-08-05 | 2022-11-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist |
CN114173816A (zh) | 2019-08-05 | 2022-03-11 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗特应性皮炎的方法 |
CN115768516A (zh) | 2020-05-22 | 2023-03-07 | 瑞泽恩制药公司 | 通过施用il-4r抑制剂治疗嗜酸细胞性食管炎的方法 |
-
2019
- 2019-05-10 JP JP2020563960A patent/JP2021523188A/ja active Pending
- 2019-05-10 EP EP19726273.6A patent/EP3793597A1/fr active Pending
- 2019-05-10 CN CN201980032103.7A patent/CN112153982A/zh active Pending
- 2019-05-10 US US16/409,164 patent/US11292847B2/en active Active
- 2019-05-10 AU AU2019270940A patent/AU2019270940A1/en active Pending
- 2019-05-10 MA MA052624A patent/MA52624A/fr unknown
- 2019-05-10 MX MX2020012064A patent/MX2020012064A/es unknown
- 2019-05-10 BR BR112020020387-4A patent/BR112020020387A2/pt unknown
- 2019-05-10 WO PCT/US2019/031801 patent/WO2019222055A1/fr unknown
- 2019-05-10 SG SG11202009371WA patent/SG11202009371WA/en unknown
- 2019-05-10 KR KR1020207035859A patent/KR20210010518A/ko unknown
- 2019-05-10 CA CA3099066A patent/CA3099066A1/fr active Pending
-
2022
- 2022-03-04 US US17/687,051 patent/US20220298250A1/en active Pending
-
2024
- 2024-01-04 JP JP2024000024A patent/JP2024038234A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
NZ769607A (en) | 2023-11-24 |
EP3793597A1 (fr) | 2021-03-24 |
MX2020012064A (es) | 2021-04-13 |
JP2021523188A (ja) | 2021-09-02 |
US11292847B2 (en) | 2022-04-05 |
KR20210010518A (ko) | 2021-01-27 |
US20190345253A1 (en) | 2019-11-14 |
JP2024038234A (ja) | 2024-03-19 |
MA52624A (fr) | 2021-03-24 |
AU2019270940A1 (en) | 2020-11-26 |
WO2019222055A1 (fr) | 2019-11-21 |
BR112020020387A2 (pt) | 2021-01-19 |
CN112153982A (zh) | 2020-12-29 |
CA3099066A1 (fr) | 2019-11-21 |
US20220298250A1 (en) | 2022-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT3515465T (pt) | Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r | |
SG11202009371WA (en) | Methods for treating atopic dermatitis by administering an il-4r inhibitor | |
IL289930A (en) | Methods for treating atopic dermatitis using an IL-4R antagonist | |
IL285201A (en) | EZH2 inhibitors for the treatment of lymphoma | |
IL274134A (en) | Methods of treating or preventing asthma by administering an IL-4R agonist | |
IL256056A (en) | ezh2 inhibitors for the treatment of lymphoma | |
EP3413852A4 (fr) | Méthodes, compositions et appareils pour le traitement du psoriasis par photothérapie | |
IL265516A (en) | Methods for treating severe allergic dermatitis by administering an il-4r inhibitor | |
EP3282629A4 (fr) | Procédé de déclaration d'état de canal et appareil associé | |
PT3107575T (pt) | Métodos de tratamento e prevenção de asma administrando um antagonista de il-4r | |
EP3229887A4 (fr) | Appareil et procédé pour traiter les maux de tête | |
EP3268087A4 (fr) | Méthodes de traitement du cancer par des inhibiteurs de ror gamma | |
IL281318A (en) | A method for treating medulloblastoma with an EZH2 inhibitor | |
EP3329018A4 (fr) | Méthodes de traitement de troubles médiés par l'hepcidine | |
EP3134120A4 (fr) | Compositions et méthodes pour le traitement de troubles liés aux cytokines | |
ZA201600048B (en) | Method for treating internal arcs | |
EP3654193A4 (fr) | Procédé pour autoriser une valeur de champ d'un champ de formulaire au moyen d'un champ de tierce partie | |
EP3302695A4 (fr) | Procédé et dispositifs de traitement des muscles | |
EP3244043A4 (fr) | Appareil et procédé de commande de soupape rge | |
EP3262065A4 (fr) | Procédés et compositions de traitement des dystroglycanopathies | |
EP3589370A4 (fr) | Méthode de traitement de la sclérose en plaques | |
EP3307775A4 (fr) | Méthodes de diagnostic et de traitement de troubles affectifs | |
EP3250218A4 (fr) | Méthodes de traitement de l'obésité | |
EP3139911A4 (fr) | Procédé de traitement d'une stéatohépatite non alcoolique avancée | |
MX2016009541A (es) | Metodo para tratar vajilla. |